证券代码：605199 证券简称：ST 葫芦娃 公告编号：2025-063 海南葫芦娃药业集团股份有限公司 关于公司股票被实施其他风险警示相关事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 海南葫芦娃药业集团股份有限公司（以下简称"公司"）2024年度内部控制被 出具否定意见审计报告，根据《上海证券交易所股票上市规则》第9.8.1条规定，公司 股票于2025年4月30日起被实施其他风险警示。 1、针对内部控制审计报告中指出的问题，公司的专项整改小组由董事长牵头，持 续联合公司审计部、财务部、研发部等深入开展全面自查。对研发流程管理、合同风险 防控、财务管理等业务场景潜在的风险进行重点复查，发现研发流程不规范的情况，已 责令研发部在规定的期限内补充与规范。 2、公司持续组织开展内部控制及各项管理制度的内部自查，进一步强化内控管理。 通过内部协同监督，对公司近期新签订的合同进行了风险排查，严格规范合同签订前的 立项与审批流程。针对研发合同，实行专项立项管理。业务部门签订合同前需提交立项 报告，由 ...

[Important Notice](index=2&type=section&id=Important%20Notice) This report guarantees the truthfulness and completeness of its content, notes unaudited financials, no profit distribution, and highlights investment risks - Company's board of directors, supervisory board, and senior management guarantee the truthfulness, accuracy, and completeness of the semi-annual report content and assume legal responsibility[3](index=3&type=chunk) - This semi-annual report is unaudited[5](index=5&type=chunk) - During the reporting period, the company will not distribute profits or convert capital reserves into share capital[6](index=6&type=chunk) - The company has thoroughly analyzed and described the major risks it may face in this report, and advises investors to be aware of investment risks[6](index=6&type=chunk) [Section I Definitions](index=4&type=section&id=Section%20I%20Definitions) This section defines key terms, company entities, and controlling parties for clear report understanding - This section clarifies that "Company, the Company, Huluwa, Huluwa Shares" all refer to Hainan Huluwa Pharmaceutical Group Co., Ltd[11](index=11&type=chunk) - Lists major subsidiaries such as Hainan Huluwa Pharmaceutical, Huluwa Technology, Guangxi Weiwei, and controlling shareholder Hainan Huluwa Investment and actual controllers Liu Jingping and Tang Xudong couple[11](index=11&type=chunk) [Section II Company Profile and Key Financial Indicators](index=4&type=section&id=Section%20II%20Company%20Profile%20and%20Key%20Financial%20Indicators) Overview of company information, stock changes to "ST Huluwa", and significant declines in revenue and net profit [I. Company Information](index=4&type=section&id=I.%20Company%20Information) Hainan Huluwa Pharmaceutical Group Co., Ltd., known as "Huluwa", is led by legal representative Liu Jingping - The company's Chinese name is Hainan Huluwa Pharmaceutical Group Co., Ltd., and its Chinese abbreviation is Huluwa[13](index=13&type=chunk) - The company's legal representative is Liu Jingping[13](index=13&type=chunk) [II. Contact Person and Contact Information](index=4&type=section&id=II.%20Contact%20Person%20and%20Contact%20Information) Provides contact details for the Board Secretary and Securities Affairs Representative - The Board Secretary is Wang Qingtao, and the Securities Affairs Representative is Wang Haiyan, both with the contact address at No. 30, Andu Road 1, Xiuying District, Haikou City, Hainan Province[14](index=14&type=chunk) [III. Brief Introduction to Changes in Basic Information](index=5&type=section&id=III.%20Brief%20Introduction%20to%20Changes%20in%20Basic%20Information) Company's registered and office addresses, website, and email remained unchanged during the reporting period - The company's registered address is No. 8, Yaogu Fourth Road, Phase II, Yaogu Industrial Park, Haikou National High-tech Zone, Haikou City, Hainan Province, and its office address is No. 30, Andu Road 1, Xiuying District, Haikou City, Hainan Province[15](index=15&type=chunk) - There were no changes in the company's basic information during the reporting period[15](index=15&type=chunk) [IV. Brief Introduction to Changes in Information Disclosure and Document Custody Locations](index=5&type=section&id=IV.%20Brief%20Introduction%20to%20Changes%20in%20Information%20Disclosure%20and%20Document%20Custody%20Locations) Specifies designated newspapers and website for information disclosure, with no changes in custody locations - The company designates Shanghai Securities News, China Securities Journal, Securities Daily, and Securities Times as information disclosure newspapers[16](index=16&type=chunk) - The website address for publishing the semi-annual report is www.sse.com.cn[16](index=16&type=chunk) [V. Brief Introduction to Company Stock](index=5&type=section&id=V.%20Brief%20Introduction%20to%20Company%20Stock) Company's A-shares are listed on the Shanghai Stock Exchange, with stock abbreviation changed to "ST Huluwa" - The company's stock type is A-shares, listed on the Shanghai Stock Exchange[17](index=17&type=chunk) - The stock abbreviation has changed from "Huluwa" to "ST Huluwa", with stock code 605199[17](index=17&type=chunk) [VII. Key Accounting Data and Financial Indicators](index=5&type=section&id=VII.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) Operating revenue and net profit significantly declined, while operating cash flow improved due to reduced payments 2025 Semi-Annual Key Accounting Data | Key Accounting Data | Current Period (Jan-Jun) | Prior Year (Adjusted) | % Change from Prior Year | | :------------------ | :----------------------- | :-------------------- | :----------------------- | | Operating Revenue | 507,670,912.42 | 888,949,451.28 | -42.89 | | Total Profit | 8,178,289.04 | 50,203,025.62 | -83.71 | | Net Profit Attributable to Shareholders of Listed Company | 2,409,780.66 | 41,092,478.86 | -94.14 | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-recurring Items) | -18,781,607.98 | 4,530,905.84 | N/A | | Net Cash Flow from Operating Activities | 14,154,022.67 | -151,118,833.90 | N/A | 2025 Semi-Annual Key Financial Indicators | Key Financial Indicators | Current Period (Jan-Jun) | Prior Year (Adjusted) | % Change from Prior Year | | :----------------------- | :----------------------- | :-------------------- | :----------------------- | | Basic Earnings Per Share (Yuan/Share) | 0.01 | 0.10 | -90.00 | | Diluted Earnings Per Share (Yuan/Share) | 0.01 | 0.10 | -90.00 | | Basic Earnings Per Share (Excluding Non-recurring Items) (Yuan/Share) | -0.05 | 0.01 | N/A | | Weighted Average Return on Net Assets (%) | 0.34 | 3.96 | Decrease by 3.62 percentage points | | Weighted Average Return on Net Assets (Excluding Non-recurring Items) (%) | -2.68 | 0.44 | Decrease by 3.12 percentage points | - Operating revenue decreased by **42.89%** year-on-year, primarily due to reduced sales of respiratory system drugs[20](index=20&type=chunk) - Net profit attributable to shareholders of the listed company decreased by **94.14%** year-on-year, mainly due to the decrease in operating revenue[21](index=21&type=chunk) - Net cash flow from operating activities increased compared to the prior year, mainly due to reduced operating payments[21](index=21&type=chunk) [IX. Non-recurring Gains and Losses Items and Amounts](index=6&type=section&id=IX.%20Non-recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) Total non-recurring gains and losses were 21.19 million yuan, primarily from government subsidies 2025 Semi-Annual Non-recurring Gains and Losses Items and Amounts | Non-recurring Gains and Losses Item | Amount (Yuan) | | :---------------------------------- | :------------ | | Disposal gains/losses of non-current assets | -323,740.80 | | Government subsidies recognized in current profit and loss | 21,625,725.13 | | Other non-operating income and expenses apart from the above | -57,072.79 | | Other gains and losses meeting the definition of non-recurring items | 135,164.90 | | Less: Income tax impact | 48,967.49 | | Minority interest impact (after tax) | 139,720.31 | | Total | 21,191,388.64 | [Section III Management Discussion and Analysis](index=7&type=section&id=Section%20III%20Management%20Discussion%20and%20Analysis) Discusses operating performance, industry trends, core competencies, and management's strategic responses to market challenges [I. Description of the Company's Industry and Main Business During the Reporting Period](index=7&type=section&id=I.%20Description%20of%20the%20Company%27s%20Industry%20and%20Main%20Business%20During%20the%20Reporting%20Period) Company focuses on children's health, with products in traditional Chinese medicine, chemical drugs, and nutritional supplements [(I) Company's Main Business Operations](index=7&type=section&id=(I)%20Company%27s%20Main%20Business%20Operations) Pharmaceutical manufacturing with a "children's full life cycle health" strategy, strong pediatric product portfolio, and API expansion - The company is a pharmaceutical manufacturing enterprise with integrated R&D, production, and sales capabilities in China, with a core strategy of "children's full life cycle health"[27](index=27&type=chunk) - The company has **111** in-production and in-sale products, of which **54** have clear pediatric dosages, covering common diseases in children aged 0-14[29](index=29&type=chunk) - Star products Xiao'er Feire Kecuan Granules and Changyanning Granules/Capsules won awards such as "2024 China Pharmacy Selected Brand"[29](index=29&type=chunk) - The company actively expands its API front-end chemical intermediate business by controlling Jiangxi Rongxing Pharmaceutical Co., Ltd., and is advancing the construction of API production workshops[31](index=31&type=chunk) [(II) Company's Main Operating Model](index=11&type=section&id=(II)%20Company%27s%20Main%20Operating%20Model) Centralized management, specialized operations, balanced procurement, "production based on sales" model, and diversified sales channels - The company implements centralized group management, with each subsidiary operating professionally; the headquarters is responsible for strategic planning, and subsidiaries for specific business implementation[35](index=35&type=chunk) - The procurement model is centrally managed by the procurement department, selecting high-quality suppliers and conducting strict on-site inspections for key materials such as traditional Chinese medicinal herbs[36](index=36&type=chunk) - The production model combines "production based on sales" and "reasonable inventory"; the Meian Children's Pharmaceutical Intelligent Manufacturing Factory has passed GMP certification, achieving automated, information-based, and intelligent production[37](index=37&type=chunk)[38](index=38&type=chunk) - The sales model primarily includes direct sales, traditional distribution, and distributor models, covering a wide marketing network including chain pharmacies, medical institutions, and e-commerce platforms[39](index=39&type=chunk)[40](index=40&type=chunk)[41](index=41&type=chunk) [(III) Market Position of the Company's Main Products](index=12&type=section&id=(III)%20Market%20Position%20of%20the%20Company%27s%20Main%20Products) Strong position in pediatric drugs, with exclusive products and extensive national essential drug and medical insurance coverage - The company specializes in pediatric drugs, primarily traditional Chinese medicine with rapidly developing chemical drugs, focusing on respiratory, digestive, and systemic anti-infective medications[42](index=42&type=chunk) - Xiao'er Feire Kecuan Granules (4g), Changyanning Capsules (0.3g), and Changyanning Granules (2g) are exclusive specification products[43](index=43&type=chunk) - Xiao'er Feire Kecuan Granules won honors such as "2023-2024 China Pharmaceutical Retail Market Potential Brand", and Changyanning Granules won honors such as "2024 China OTC Product Comprehensive Statistical Ranking Second Place"[43](index=43&type=chunk) - The company has **63** drugs included in the National Essential Drug List and **105** drugs in the National Medical Insurance Catalog[43](index=43&type=chunk) [(IV) Industry Overview](index=13&type=section&id=(IV)%20Industry%20Overview) Pharmaceutical industry faces policy adjustments, TCM grows with standardization, and pediatric drug market expands with policy support - From January to June 2025, operating revenue of pharmaceutical manufacturing enterprises above designated size decreased by **1.2%** year-on-year, and total profit decreased by **2.8%** year-on-year, indicating an overall adjustment trend in the industry[45](index=45&type=chunk) - The National Healthcare Security Administration further expanded the scope of centralized procurement, optimized the basic medical insurance catalog, and strengthened refined supervision of medical insurance funds[45](index=45&type=chunk) - The traditional Chinese medicine industry is steadily advancing under continuous policy support from the "14th Five-Year Plan"; the National Administration of Traditional Chinese Medicine issued the "Traditional Chinese Medicine Standardization Action Plan (2024-2026)", aiming to complete the formulation of **180** domestic standards and **30** international standards by the end of 2026[47](index=47&type=chunk) - Policy support for pediatric traditional Chinese medicine continues to increase, with multiple provinces raising the medical insurance reimbursement ratio for pediatric traditional Chinese medicine, and the priority review system for pediatric drugs remains effective[49](index=49&type=chunk) - The company has achieved results in developing suitable pediatric dosages and innovative drugs; Terbutaline Sulfate Inhalation Solution has been approved, Phase III clinical trials for Xiao'er Huaji Granules have completed enrollment, and Phase II clinical trials for Xiao'er Malong Zhike Pingchuan Granules have successfully concluded[52](index=52&type=chunk) [(V) Industry Cyclical Characteristics](index=15&type=section&id=(V)%20Industry%20Cyclical%20Characteristics) Pharmaceutical industry has rigid demand with no obvious cycles, but specific drug sales show seasonality - The pharmaceutical industry has strong rigid demand and no obvious cyclical changes[54](index=54&type=chunk) - Sales of specific drug varieties exhibit some seasonality due to the high incidence period of their indications being affected by seasonal and environmental factors[54](index=54&type=chunk) [(VI) Company's Industry Position](index=15&type=section&id=(VI)%20Company%27s%20Industry%20Position) Prominent in pediatric medicine, recognized as a top enterprise in TCM and Hainan's manufacturing sector - The company is a Vice Chairman Unit of the Pediatric Branch of the China Association of Traditional Chinese Medicine and a Vice President Unit of the Pediatric Branch of the China Ethnic Medicine Association[55](index=55&type=chunk) - The company ranked **20th** among the Top 50 Manufacturing Enterprises in Hainan Province in 2024 and among the Top 50 Enterprises in Comprehensive Competitiveness of Traditional Chinese Medicine Industry in 2024[55](index=55&type=chunk) - Received multiple honors such as "Leading Force China Pharmaceutical High-Quality Development Achievement Enterprise" and "Excellent Brand Enterprise of Chinese Ethnic Medicine"[55](index=55&type=chunk) [II. Discussion and Analysis of Operating Performance](index=16&type=section&id=II.%20Discussion%20and%20Analysis%20of%20Operating%20Performance) H1 2025 saw revenue and profit decline, prompting R&D, market, digital, quality, and risk control improvements [(I) Continuously Advancing R&D Innovation](index=16&type=section&id=(I)%20Continuously%20Advancing%20R%26D%20Innovation) Focused on "precise R&D" in pediatric areas, with new drug approvals, clinical trials, and generic drug evaluations - The company holds **341** drug approvals, with **7** Class 1 innovative drugs and **9** Class 2 new drugs (including 3 traditional Chinese medicines and 6 chemical drugs) at various R&D stages[58](index=58&type=chunk) - Feire Kecuan Granules (Class 2.3 improved traditional Chinese medicine new drug) received the "Drug Clinical Trial Approval Notice", adding "influenza with heat-toxin invading the lung syndrome" indication and "adult" applicable population[58](index=58&type=chunk) - The company and its subsidiaries successfully obtained **4** drug registration approvals, including Salbutamol Sulfate Inhalation Solution, Esomeprazole Sodium for Injection, Calcitriol Soft Capsules, and Pregabalin Oral Solution[59](index=59&type=chunk) - **3** varieties passed the generic drug quality and efficacy consistency evaluation, and production applications for **25

Core Viewpoint - The Shanghai Stock Exchange has criticized ST Houlvwa for accounting errors and has mandated corrective actions following a report of premature revenue recognition and pricing anomalies in 2023 [1][2]. Group 1: Company Financial Adjustments - ST Houlvwa discovered that some sales in 2023 had prematurely recognized revenue, leading to discrepancies in financial data reported in periodic reports [2]. - The company will adjust its financial statements for 2023 and the first half of 2024, with net profit reductions of approximately 95.64 million yuan and 37.66 million yuan, representing 89.81% and 47.82% of the pre-adjustment amounts, respectively [2]. - Total profit adjustments for the same periods are approximately 108 million yuan and 4.40 million yuan, accounting for 80.05% and 46.73% of the pre-adjustment amounts, respectively [2]. Group 2: Company Governance and Disciplinary Actions - The Shanghai Stock Exchange's disciplinary committee has issued a public reprimand to the company's then-chairman and general manager Liu Jingping, as well as the then-financial director Yu Hui, due to the identified violations [2]. - The disciplinary actions are based on the company's failure to comply with the regulations outlined in the Stock Listing Rules and related guidelines [2]. Group 3: Company Market Position - As of the latest report, ST Houlvwa has a market capitalization of 3.8 billion yuan [4]. - The company's revenue for the year 2024 is entirely derived from the pharmaceutical manufacturing sector, indicating a focused business model [3].

Core Viewpoint - The Shanghai Stock Exchange has issued a decision to publicly criticize Hainan Huluwa Pharmaceutical Group Co., Ltd. (stock abbreviation: ST Huluwa) for inaccurate financial data disclosures in multiple periodic reports, involving significant amounts and high correction ratios [1] Summary by Relevant Sections - **Company Accountability** - The decision highlights that the then Chairman and General Manager Liu Jingping, along with the then Chief Financial Officer Yu Hui, failed to fulfill their duties and are responsible for the company's violations [1] - **Disciplinary Actions** - The Shanghai Stock Exchange has decided to publicly criticize Hainan Huluwa Pharmaceutical Group Co., Ltd., Liu Jingping, and Yu Hui for their roles in the inaccurate financial disclosures [1]

Meeting Overview - The first temporary shareholders' meeting of Hainan Huluwa Pharmaceutical Group Co., Ltd. for the year 2025 was held on August 20, 2025, at the company's meeting room in Haikou City, Hainan Province [1] - The meeting was chaired by the company's chairman, Liu Jingping, and utilized a combination of on-site and online voting methods, complying with the Company Law and the company's articles of association [1][2] Attendance and Voting - The meeting was attended by 6 current directors, 3 independent directors, 3 supervisors, and the board secretary, along with all senior management personnel [1] - The voting on the non-cumulative proposals was conducted with more than half of the valid voting rights held by attending shareholders (including proxies) [2] Resolutions Passed - The following resolutions were approved during the meeting: 1. Appointment of an accounting firm to audit the financial statements for the year 2023 [1] 2. Re-election of candidates for the third board of directors [1] Legal Verification - The meeting was witnessed by Beijing Guofeng Law Firm, with lawyers providing a legal opinion confirming that the meeting's procedures and voting results were lawful and valid [2]

证券代码：605199 证券简称：ST 葫芦娃 公告编号：2025-059 海南葫芦娃药业集团股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 1、出席会议的股东和代理人人数 | 842 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 307,170,002 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 76.7716 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，董事长刘景萍女士主持会议。采用现场投 票和网络投票相结合的方式召开，会议的召集、召开、表决程序和方式均符合《公 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 8 月 20 日 (二)股东大会召开的地点：海南省海口市秀英区安读一路 30 号公司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及 ...

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于海南葫芦娃药业集团股份有限公司 2025 年第一次临时股东大会的 法律意见书 国枫律股字[2025]A0398 号 致：海南葫芦娃药业集团股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见 证贵公司2025年第一次临时股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称 "《股东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证 券法律业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简 称"《证券法律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《海 南葫芦娃药业集团股份有限公司章程》（以下简称"《公司章程》"）的规定，就本次 会议的召集与召开程序、召集人资格、出席会议人员资格、会议表决程序及表决结果 ...

Market Overview - The Shanghai Composite Index closed at 3686.34 points, with a gain of 0.56% [1] - The total trading volume of A-shares reached 1,328.277 billion yuan [1] Stocks with Death Cross - A total of 52 A-shares experienced a death cross, where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - *ST Gao Hong: 5-day MA at 2.09 yuan, 10-day MA at 2.13 yuan, difference of -1.93% [1] - Bu Ke Co.: 5-day MA at 94.86 yuan, 10-day MA at 95.89 yuan, difference of -1.08% [1] - Rong Tai Co.: 5-day MA at 32.17 yuan, 10-day MA at 32.47 yuan, difference of -0.92% [1] Additional Stock Performance - Other stocks showing a death cross include: - He Chuan Technology: 5-day MA at 47.55 yuan, 10-day MA at 47.92 yuan, difference of -0.78% [1] - Xin Xun Da: 5-day MA at 13.82 yuan, 10-day MA at 13.92 yuan, difference of -0.70% [1] - Stocks with minor changes in their moving averages include: - ST Xue Fa: 5-day MA at 3.87 yuan, 10-day MA at 3.89 yuan, difference of -0.51% [1] - Huang Ting International: 5-day MA at 2.92 yuan, 10-day MA at 2.94 yuan, difference of -0.44% [1]

Core Points - The company is appointing Zhengdan Zhiyuan (Shenzhen) CPA Firm to audit the revised 2023 financial statements due to a change in profit and loss status from profit to loss as per the regulatory requirements [4][10] - The board of directors has approved the appointment of the CPA firm with a unanimous vote and is now seeking shareholder approval [10][12] Group 1: Appointment of CPA Firm - The CPA firm Zhengdan Zhiyuan (Shenzhen) was selected based on its qualifications and ability to meet the company's auditing needs for the revised financial statements [9][10] - The firm has a history of providing auditing services, with 16 listed company clients in 2024, including 13 in manufacturing and 2 in information technology [6][9] - The firm has no recent criminal or administrative penalties, indicating a strong compliance record [7][8] Group 2: Board of Directors' Actions - The board has nominated Mr. Wang Qingtang as a candidate for a non-independent director position, pending shareholder approval [12] - The nomination is part of the company's efforts to enhance its corporate governance structure [12] - Mr. Wang has relevant experience and qualifications, having served in various roles within the company since 2006 [13]

证券代码：605199 证券简称：ST 葫芦娃 公告编号：2025-058 海南葫芦娃药业集团股份有限公司 关于补选董事的公告 特此公告。 海南葫芦娃药业集团股份有限公司董事会 2025 年 8 月 6 日 1 附：个人简历 王清涛：男，1982 年出生，中国国籍，无境外永久居留权，大学本科学历，高级人 力资源管理师，2006 年 3 月至 2007 年 3 月，担任海口电视台经济频道编导，2007 年 3 月至 2015 年 2 月，担任海南康迪医药有限公司行政人事经理，2015 年 3 月至 2019 年 2 月担任本公司行政人事经理，2019 年 2 月至 2021 年 6 月担任本公司行政部经理，2021 年 6 月至今担任本公司董事会秘书。目前兼任江西荣兴药业有限公司董事。 王清涛先生通过杭州中嘉瑞管理合伙企业（有限合伙）间接持有公司 273,900 股股 份，占公司总股本的 0.07%，与公司实际控制人及董事、高级管理人员和持股 5%以上的 公司股东均不存在关联关系。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ...